| Audience | Patients, clinicians, and readers trying to understand what a cortisol association can and cannot say about frequent cannabis use. |
| Primary Topic | Frequent cannabis use, waking cortisol, and the cortisol awakening response. |
| Source | Read the peer-reviewed primary paper |
Cannabis and Waking Cortisol: What the Study Did Not Prove
A small observational study found that 39 frequent cannabis users had higher cortisol at waking than 43 controls, but the groups did not differ in the cortisol awakening response. The result does not show that cannabis caused stress-system dysregulation or that waking cortisol can diagnose problematic use. A careful reading keeps the positive finding, the negative replication result, and the study’s limits together.
The earlier article summarized the same study as evidence that frequent cannabis use may dysregulate the HPA axis and potentially worsen long-term stress resilience.
| Study Type | Peer-reviewed observational group comparison |
| Population | 39 adults with frequent cannabis use and 43 healthy controls |
| Sampling | Saliva at awakening, 30 minutes later, and in the evening |
| Duration | Two consecutive weekdays |
| Primary Comparison | Cortisol awakening response between frequent-use and control groups |
| Main Negative Finding | No significant group difference in cortisol awakening response, p = 0.23 |
| Main Positive Finding | Higher cortisol at awakening in the frequent-use group, p = 0.047 |
| Within-Group Association | Waking cortisol was associated with cannabis-related consequences, p = 0.007 |
| Major Limitation | Observational design cannot establish directionality or causation |
| Journal | Cannabis |
| Published | June 9, 2026 |
| DOI | 10.26828/cannabis/2026/000390 |
Participants reported subjective stress and collected saliva at waking, 30 minutes later, and in the evening on two consecutive weekdays.
The investigators compared the cortisol awakening response between groups and examined relationships among subjective stress, cortisol, cannabis-use status, and cannabis-related consequences.
The groups did not differ significantly in the cortisol awakening response. This matters because earlier work had suggested a blunted response among chronic users.
A negative replication result should remain visible in the interpretation. It narrows any claim that frequent use produces a consistent alteration in the morning cortisol rise.
At the first waking sample, the frequent-use group had higher cortisol than controls. Within the study, higher waking cortisol was also associated with greater cannabis-related consequences.
This is a potentially useful signal for future research, but it is not yet a validated biomarker and should not be used as a diagnostic shortcut.
The study cannot determine whether frequent cannabis use altered waking cortisol, whether people experiencing more stress were more likely to use frequently, or whether shared factors influenced both.
Sleep timing, withdrawal, psychiatric symptoms, other substance use, collection adherence, product potency, and cannabinoid composition are among the factors that larger longitudinal work should characterize more fully.
The practical response is neither dismissal nor alarm. Clinicians can ask why a person uses cannabis, how often, at what time, with what products, and whether use is accompanied by withdrawal, sleep disruption, anxiety, or unwanted consequences.
Those questions are clinically useful now. Ordering cortisol tests or declaring chronic endocrine harm on the basis of this paper is not supported.
Stress and cannabis use can plausibly influence one another in both directions. People may use cannabis in response to stress, while frequent use, withdrawal, sleep disruption, and use-related consequences may also shape stress experience.
That bidirectional possibility is exactly why cross-sectional biomarker findings require restraint. A plausible mechanism is not the same as demonstrated causation.
The detail I would protect from the headline is that the cortisol awakening response itself did not differ between groups. The positive finding was narrower: a higher first morning value in frequent users.
That is worth studying, particularly because it tracked with use-related consequences, but it is not enough to tell a patient that cannabis caused endocrine dysfunction. Better counseling starts with patterns, context, symptoms, and consequences rather than a dramatic biomarker story.
How to Read a Cortisol Association Without Turning It Into Causation
Biomarker studies can sound more definitive than their designs allow.
The right interpretation separates the exact measure that changed from the one that did not, then asks whether the design can establish direction.
Four questions that keep the result in proportion
What changed?
Cortisol at awakening was higher in the frequent-use group.
What did not change?
The rise from waking to 30 minutes later did not differ significantly between groups.
Can the study establish cause?
No. Cannabis use was observed, not assigned, and temporal direction was not established.
What is clinically justified?
Ask about use patterns, stress, sleep, withdrawal, and consequences while awaiting longitudinal replication.
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses.
A Marker Is Not a Diagnosis
A higher waking cortisol value in one small group comparison does not diagnose a stress disorder or prove that cannabis damaged the stress system.
The finding is a reason for better questions about sleep, stress, withdrawal, use patterns, and symptoms, not a reason for self-diagnosis.
The Use Pattern and the Reason for Use Both Matter
Frequent use can be both an exposure and a response to pre-existing stress. Cross-sectional data cannot cleanly separate those directions.
A useful history includes frequency, timing, product type, sleep, anxiety symptoms, withdrawal, and the consequences that the patient associates with use.
The Main Replication Result Was Negative
The study was designed in part to examine the cortisol awakening response, the change from waking to 30 minutes later. That response did not differ significantly between groups.
The positive finding concerned the waking baseline, and it should not be expanded into a claim that the entire daily stress rhythm was proven to be dysregulated.
Two Weekdays and Three Daily Samples Define the Boundary
Participants collected saliva at waking, 30 minutes later, and in the evening on two consecutive weekdays.
That design can detect group associations, but it cannot establish long-term trajectories, eliminate all timing error, or determine which factor came first.
Stress Relief and Stress Biology Are Different Questions
A person can report short-term relief while also having a complicated relationship among chronic stress, sleep, dependence, and use consequences.
This paper did not test cannabis as an anxiety treatment and did not compare clinical therapies.
Consequences Deserve Attention Without Overreach
Within the frequent-use group, higher waking cortisol was associated with more cannabis-related consequences.
That association can support screening and conversation, but it still does not show that lowering cannabis use will necessarily normalize cortisol or improve a specific condition.
Headlines Can Reverse the Weight of the Findings
A headline about higher cortisol can sound causal and alarming even when the study found no group difference in its named awakening-response measure.
Accurate communication keeps the negative and positive findings together and identifies the study as observational.
Longitudinal Replication Is the Next Useful Step
Larger studies should track people over time, standardize collection adherence, characterize THC and CBD exposure, and measure sleep, withdrawal, psychiatric symptoms, and other substance use.
Those designs would better test whether waking cortisol predicts problematic use, follows it, or reflects shared underlying stress.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
When a new paper overlaps with earlier CED Clinic coverage, we preserve the chain instead of hiding the overlap. These links point to older related posts so readers can compare what is new, what is repeated, and how the evidence has moved.
The earlier article summarized the same study as evidence that frequent cannabis use may dysregulate the HPA axis and potentially worsen long-term stress resilience.
The endocannabinoid system can only do so much when Murphy’s Law intersects with your stress management protocol. A moment of silence for fallen flower and dashed cortisol relief. Via r/trees Further Reading Cannabis Po…
GLP-1 weight loss drugs clinical evidence and outcomes reveal why some patients experience stalled weight loss despite therapy. Factors such as diet, medication adherence, and metabolic conditions influence results. Und…
Senobi breathing weight loss has shown early signals of reducing body fat in some women, with a reported 3% reduction over 30 days. The clinical evidence suggests sympathetic nervous system activation may influence lipi…
Boops Pets introduces NASC audited canine calming chews featuring clinical grade KSM 66 Ashwagandha. These supplements address pet anxiety with quality assurance. NASC auditing ensures manufacturing standards but not cl…
CBD gummies for dog separation anxiety are increasingly popular among pet owners seeking alternative treatments. While anecdotal reports suggest benefits, rigorous clinical evidence remains limited. Understanding the sa…
Salivary cortisol measurement cannabis protocols offer a non-invasive way to assess stress response in patients using cannabis therapeutically. This webinar highlights improved collection and analysis methods to enhance…
Brain-immune responses to stress vary significantly among individuals, influencing anxiety disorder development. This variability affects HPA axis regulation and immune function. Understanding these responses is key to…
Frequently Asked Questions
What did the cannabis waking cortisol study investigate?
It compared subjective stress and salivary cortisol patterns in 39 adults with frequent cannabis use and 43 healthy controls.
Did frequent cannabis users have a different cortisol awakening response?
No. The change from waking to 30 minutes later did not differ significantly between the groups.
What cortisol result did differ between groups?
The frequent-use group had higher cortisol at the waking sample, and that measure was associated with cannabis-related consequences within the study.
Does the study prove cannabis caused higher waking cortisol?
No. The observational comparison cannot determine whether cannabis use caused the difference, whether stress contributed to frequent use, or whether another factor influenced both.
Was this a cannabis treatment trial?
No. Researchers did not assign cannabis, test a therapeutic product, or compare treatments for anxiety or stress.
How were cortisol samples collected?
Participants collected saliva at awakening, 30 minutes after awakening, and in the evening on two consecutive weekdays.
Can a waking cortisol value diagnose problematic cannabis use?
No. The authors described it as a possible research marker that requires further investigation, not a validated diagnostic test.
Does the result mean frequent cannabis use worsens anxiety?
No. The study did not establish a causal effect on anxiety symptoms or show that cannabis worsened a psychiatric condition.
What should clinicians take from the paper?
It supports careful discussion of use frequency, stress, sleep, withdrawal, and cannabis-related consequences while avoiding causal claims from a single biomarker study.
What research would clarify the finding?
Larger longitudinal studies with detailed cannabinoid exposure, collection-adherence checks, and measurement of sleep, psychiatric symptoms, withdrawal, and other substance use would help establish directionality.
